<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35086595</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1092-8529</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>CNS spectrums</Title>
          <ISOAbbreviation>CNS Spectr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Treatment strategies for clozapine-induced nocturnal enuresis and urinary incontinence: a systematic review.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>12</EndPage>
          <MedlinePgn>1-12</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1017/S1092852922000050</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clozapine is the most effective medication for treatment-refractory schizophrenia but is associated with significant adverse drug reactions, including nocturnal enuresis and urinary incontinence. This side effect can be burdensome and lead to medication nonadherence and psychotic relapse. Evidence to guide treatment of clozapine-induced nocturnal enuresis and urinary incontinence is sparse. We therefore aimed to synthesize the evidence base to guide management for clinicians, patients, and their carers.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched PubMed, Embase, PsycInfo, CINAHL, and the Cochrane Trial Registry databases from inception to May 2021 for publications on management of clozapine-induced nocturnal enuresis and urinary incontinence using a PROSPERO preregistered search strategy.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 22 case reports and case series describing 74 patients. Interventions included clozapine dose reduction, nonpharmacological treatment, and pharmacological treatments. Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence. Balancing evidence for effectiveness against risk of adverse effects, we developed a management framework for clozapine-induced nocturnal enuresis and urinary incontinence.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Following assessment of urological, psychiatric, pharmacological, and common comorbid medical issues, first-line treatments should be nonpharmacological, including bathroom alarms, voiding before bedtime, and nocturnal fluid restriction. If these interventions do not provide adequate relief, aripiprazole should be trialed. Desmopressin may be considered for severe refractory cases, but monitoring for hyponatremia is essential.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tanzer</LastName>
            <ForeName>Timothy</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-5924-3320</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Warren</LastName>
            <ForeName>Nicola</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Metro South Addiction and Mental Health Service, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McMahon</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barras</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kisely</LastName>
            <ForeName>Steve</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Metro South Addiction and Mental Health Service, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brooks</LastName>
            <ForeName>Emily</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Emily</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siskind</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Metro South Addiction and Mental Health Service, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>CNS Spectr</MedlineTA>
        <NlmUniqueID>9702877</NlmUniqueID>
        <ISSNLinking>1092-8529</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Schizophrenia</Keyword>
        <Keyword MajorTopicYN="N">clozapine</Keyword>
        <Keyword MajorTopicYN="N">nocturnal enuresis</Keyword>
        <Keyword MajorTopicYN="N">systematic review</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35086595</ArticleId>
        <ArticleId IdType="doi">10.1017/S1092852922000050</ArticleId>
        <ArticleId IdType="pii">S1092852922000050</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
